Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A humanized antibody with specificity for hepatitis B surface antigen

C J Ryu1, E A Padlan, B R Jin

  • 1Antibody Engineering Research Unit, Korea Research Institute of Bioscience and Biotechnology, KIST, Yuseong, Taejeon, Korea.

Human Antibodies and Hybridomas
|January 1, 1996
PubMed
Summary

A new humanized antibody, HuS10, shows high potential for preventing hepatitis B virus (HBV) infection. It neutralizes HBV infection with significantly higher activity than existing hepatitis B immune globulin (HBIG).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neutrophil-lymphocyte ratio and hypersensitive C-reaction protein are associated with miscarriage during the second trimester of pregnancy.

Journal of biological regulators and homeostatic agents·2021
Same author

Establishment of a Gallbladder Cancer-Specific Survival Model to Predict Prognosis in Non-metastatic Gallbladder Cancer Patients After Surgical Resection.

Digestive diseases and sciences·2018
Same author

Gene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2.

Cancer gene therapy·2016
Same author

Tetrafluoroethane (R134a) hydrate formation within variable volume reactor accompanied by evaporation and condensation.

The Review of scientific instruments·2015
Same author

Genetic transformation and plant regeneration of watermelon using Agrobacterium tumefaciens.

Plant cell reports·2013
Same author

Conversion of twice-daily tacrolimus to once-daily tacrolimus formulation in stable pediatric kidney transplant recipients: pharmacokinetics and efficacy.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2013

Area of Science:

  • Immunology
  • Virology
  • Biotechnology

Background:

  • Hepatitis B virus (HBV) infection poses a significant global health challenge.
  • Current prevention strategies, like hepatitis B immune globulin (HBIG), have limitations.
  • Development of novel therapeutic antibodies is crucial for combating HBV.

Purpose of the Study:

  • To characterize the binding specificity of murine monoclonal antibody H67.
  • To develop a humanized antibody (HuS10) with enhanced therapeutic potential against HBV.
  • To evaluate the neutralizing capacity and affinity of HuS10 against HBV.

Main Methods:

  • Characterization of monoclonal antibody H67 for epitope recognition.
  • Construction of humanized antibody HuS10 by grafting antibody regions.

Related Experiment Videos

  • Affinity determination and in vitro neutralization assays using human hepatocyte cultures.

    • Main Results:

    • H67 recognizes a disulfide-bond-dependent conformational epitope on hepatitis B surface antigen.
    • HuS10 demonstrated an affinity comparable to H67 (8 x 10^8 M^-1).
    • HuS10 exhibited approximately 2,000-fold higher specific activity than polyclonal HBIG in neutralizing HBV infection.

    Conclusions:

    • The humanized antibody HuS10 is a promising candidate for HBV prevention and treatment.
    • HuS10's high neutralizing activity suggests potential to replace or augment current HBIG therapies.
    • Further development of HuS10 could lead to improved strategies against HBV infection.